In 1865, German pathologist Rudolf Virchow discovered a pearl-like grayish-white tumor entrenched in the abdomen of a 3-year-old boy during an autopsy in Berlin, with rose-like cell clusters inside. This discovery, named "neuroblastoma," marked the beginning of the most dramatic tumor conquest in medical history.
In 1947, only 1 out of 22 children admitted to Boston Children's Hospital survived for more than 1 year. In desperation, pediatrician Sidney Farber tried injecting nitrogen mustard (improved from World War II chemical weapons) into the tumor, which surprisingly shrank the tumor in some children. This accidental discovery, like a meteor break through the darkness, illuminated the eve of the chemotherapy era.
The molecular mechanism of neuroblastoma can be called a "textbook of cancer evolution":
Stuck accelerator: MYCN gene amplification (occurring in 25% of cases) leads to continuous activation of cell division signals
Failed brake: ALK gene mutation (8% of cases) disables the cell apoptosis program
Disrupted navigation: 1p36 chromosome deletion (30% of cases) damages tumor suppressor genes
Immortality code: Telomerase reverse transcriptase (TERT) rearrangement endows infinite division ability
A 2023 study in Nature Cancer revealed a more astonishing mechanism: tumor cells secrete exosome-carried miR-375, which hijacks bone marrow mesenchymal stem cells like a Trojan horse, transforming them into "accomplices" of metastatic cancer cells. This cross-cell manipulation results in:
• 5-fold increase in the formation rate of bone marrow metastases
• 80% improvement in the spread efficiency of drug-resistant genes
• IL-6 concentration in the tumor microenvironment reaching 500 times the normal level
Detection of vanillylmandelic acid (VMA) and homovanillic acid (HVA) in urine, with an accuracy rate of only 68%
123I-MIBG imaging technology increased the detection rate of metastases to 95%, and MRI diffusion-weighted imaging can identify 0.5cm lesions
Liquid biopsy detects circulating tumor DNA (ctDNA) with a sensitivity of 0.01%, and AI systems can predict recurrence 11 months in advance by analyzing ctDNA methylation profiles
Japan's ultra-sensitive MIBG-PET/CT system can detect tiny metastases containing only 50 tumor cells. The diagnostic process established by the EU's "Precision Neuroblastoma" program has shortened the diagnosis time from 6 weeks to 72 hours.
US COG regimen: Cyclophosphamide + Topotecan + Vincristine increased the 3-year survival rate of high-risk groups from 15% to 50%, with hearing impairment rate controlled at 8%
Proton therapy reduced the incidence of scoliosis from 32% with traditional radiotherapy to 1.5% (10-year data from Massachusetts General Hospital)
GD2 monoclonal antibody (Dinutuximab) combined with GM-CSF and IL-2 increased the 5-year survival rate of high-risk groups by 18%, and received FDA breakthrough certification in 2015
ALK inhibitor Lorlatinib, targeting ALK mutant types, achieved an objective response rate of 63% (2022 NEJM study)
The International Neuroblastoma Risk Group (INRG) database integrates 47,000 cases worldwide, with AI models predicting recurrence risk with 91% accuracy
Dual-target GD2/B7H3 CAR-T showed amazing results in Phase I trials: 7 out of 12 refractory patients achieved complete remission, with progression-free survival for 18 months
Histone deacetylase inhibitor Panobinostat combined with chemotherapy increased the clearance rate of bone marrow metastases by 3 times
A German team found that tumor cells rely on inositol metabolism, and inhibitor LCI-066 reduced tumor volume by 89% in animal models
China-developed drug-loaded nanoparticles can cross the blood-brain barrier, increasing the control rate of brain metastases from 11% to 67%
In Mumbai, India, bioengineers developed a VMA detection test paper costing only $10, increasing the diagnosis rate in rural areas by 5 times. The 3D printing center in São Paulo, Brazil, customizes radiotherapy brackets for children, reducing positioning errors from 5mm to 0.3mm
In April 2024, the GD2 vaccine jointly developed by China, Japan, and Germany published Phase III results in The Lancet: the 5-year event-free survival rate of the vaccinated group reached 94%. Africa's first artificial intelligence diagnostic center was launched in Nairobi, identifying orbital metastases through fundus photography with 98% accuracy.
From Virchow's microscope to today's gene editing, this 160-year battle has witnessed the brilliance of human wisdom. When the US FDA approved the first MYCN inhibitor, when Shanghai Jiao Tong University mapped the holographic atlas of tumor cell evolution, and when Africa's first proton therapy device was completed in Cape Town — this is a victory belonging to all mankind.
Dr. Susan Cohn, President of the International Society of Pediatric Oncology, said:
"We are standing at the threshold of curing high-risk neuroblastoma. In the next decade, personalized treatment plans based on multi-omics analysis will push the survival rate beyond 80%, giving every child the right to see the sun tomorrow."
In this journey spanning three centuries, every technological breakthrough, every data sharing, and every successful treatment is reshaping the possibilities of life. When dawn pierces the darkness, humanity will ultimately prove: in the game between life and death, science and compassion are always the most powerful weapons.
EN
CN